Evidence map›Paper›PMID 42100636›Full record

ReviewADMET & DMPK2026

Linking biomimetic binding measurements to pharmacokinetic models of volume of distribution and hepatic clearance.

Klara Valko

Abstract readReview
In one paragraph

Review in ADMET & DMPK, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Klara ValkoBio-Mimetic Chromatography, Ltd. Business &Technology Centre, Bessemer Drive, Stevenage, Herts. SG1 2DX United Kingdom.ORCID https://orcid.org/0000-0003-4605-2941

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: The steady-state volume of distribution reflects the extent to which drugs partition between plasma and tissues and is closely related to the tissue-to-plasma partition coefficient. In pharmacokinetics, different modelling frameworks have led to ongoing debate regarding the role of plasma protein binding and the importance of unbound drug exposure in determining both distribution and clearance. This review aims to clarify the relationship between distribution and elimination models and to assess how experimental binding measurements can support their mechanistic interpretation. Experimental approach: Established pharmacokinetic relationships linking volume of distribution ( Key results: The analysis shows that distribution and clearance models describe complementary aspects of drug disposition rather than contradictory processes. Tissue binding, as reflected by phospholipid affinity measured by IAM chromatography, plays a dominant role in determining Conclusion: This work demonstrates that biomimetic binding measurements provide a mechanistically meaningful bridge between physicochemical properties and pharmacokinetic behaviour. By integrating experimental binding data with pharmacokinetic models, the study advances understanding of how distribution and clearance are linked, supporting more informed decision-making in early drug discovery while highlighting that clearance remains influenced by additional factors beyond non-specific binding.

Indexed as

biomimetic chromatographyNon-specific bindingpharmacokineticsplasma protein bindingtissue binding

Identifiers

PMID42100636
PMCPMC13147519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.